Echo Therapeutics, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q3 FY2016 As of Sep 30, 2016	Q2 FY2016 As of Jun 30, 2016	Q1 FY2016 As of Mar 31, 2016	Q4 FY2015 As of Dec 31, 2015	Q3 FY2015 As of Sep 30, 2015	Q2 FY2015 As of Jun 30, 2015	Q1 FY2015 As of Mar 31, 2015	Q4 FY2014 As of Dec 31, 2014	Q3 FY2014 As of Sep 30, 2014	Q2 FY2014 As of Jun 30, 2014	Q1 FY2014 As of Mar 31, 2014	Q4 FY2013 As of Dec 31, 2013	Q3 FY2013 As of Sep 30, 2013	Q2 FY2013 As of Jun 30, 2013	Q1 FY2013 As of Mar 31, 2013	Q4 FY2012 As of Dec 31, 2012	Q3 FY2012 As of Sep 30, 2012	Q2 FY2012 As of Jun 30, 2012	Q1 FY2012 As of Mar 31, 2012	Q4 FY2011 As of Dec 31, 2011
Current Assets:
Cash and cash equivalents
Current portion of deferred financing costs
Other assets
Prepaid and other
Total current assets

Computer equipment
Office and laboratory equipment (including assets under capitalized leases)
Furniture and fixtures
Manufacturing equipment
Leasehold improvements
Property and equipment, at cost
Less-Accumulated depreciation and amortization
Property and equipment, net
Other Assets:
Restricted cash
Intangible assets, net
Deferred financing costs
Cash restricted pursuant to letters of credit
Accounts receivable
Stock subscriptions receivable
Current portion of deferred financing costs
Capitalized software development costs
Other
Total other assets
Total assets

Current Liabilities:
Accounts payable
Accrued and other
Secured convertible notes, net
Bridge loans
Deferred revenue from licensing arrangements, current portion
Current portion of capital lease obligation
Premium financing
Derivative liabilities
Total current liabilities
Capital lease obligation, net of current portion
Note payable, net of discount
Deferred revenue, net
Total liabilities

Series C, $0.01 par value, authorized 10,000 shares, issued and outstanding 9,974.185 and 4,918.100 shares at December 31, 2011 and 2010, respectively
Series D, $0.01 par value, authorized 3,600,000 shares, issued and outstanding 3,006,000 shares at December 30, 2011 (preference in liquidation of $3,006,000 at December 31, 2011)
Series C, $0.01 par value, authorized 10,000 shares, issued and outstanding 1,000 shares at March 31, 2014 and December 31, 2013
Series D, $0.01 par value, authorized 3,600,000 shares, issued and outstanding 1,000,000 shares at March 31, 2014 and December 31, 2013(preference in liquidation of $1,000,000)
Series E, $0.01 par value, authorized 1,748,613 shares, issued and outstanding 1,748,613 shares at March 31, 2014 and December 31, 2013
C - 10,000 shares authorized; issued and outstanding 1,000 shares
D - 3,600,000 shares authorized; issued and outstanding 1,000,000 shares
E - 1,748,613 shares authorized, issued and outstanding
F - 5,000,000 shares authorized; issued and outstanding 3,555,180 and 840,336 shares, respectively
Preferred Stock, $0.01 par value; 40,000,000 shares authorized: Convertible Series C, D, E, F
Series C Preferred Stock
Series D Preferred Stock
Series E Preferred Stock
Series F Preferred Stock
Common stock, $0.01 par value; 150,000,000 shares authorized; issued and outstanding 11,512,586 and 11,124,496 shares, respectively
Additional paid-in capital
Common stock subscribed for but not paid for or issued,33,333 shares at December 31, 2011
Common stock subscribed for but not paid for or issued, 33,333 shares at December 31, 2011
Common stock subscription
Subscriptions receivable: Series F - 200,000 shares
Accumulated deficit
Total stockholders' deficit
Total liabilities and stockholders' deficit

Comments